Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

You may also be interested in...



As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?

SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.

Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff

SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area

Merck Invests In China Oncology Start-up BeiGene

Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC086543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel